Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML

Cancer Cell International

Yangqiu Li³  Bo Li¹  Xiuli Wu¹  Lijian Yang¹  Fan Zhang¹  Ling Xu¹  Xu Wang²  Yuhong Lu¹  Shaohua Chen¹  Li Shi¹ 

[1] Institute of Hematology, Jinan University, Guangzhou, 510632, China;Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, China;Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering, Jinan University, Guangzhou, 510632, China

关键词: Acute myeloid leukemia;    T cells;    NF-κB;    A20;    MALT1;   

Others  :  793996
DOI  :  10.1186/1475-2867-13-37

 received in 2013-04-08, accepted in 2013-04-24,  发布年份 2013

【 摘 要 】

To elucidate the characteristics of T-cell receptor (TCR) signal transduction in T-cells from acute myeloid leukemia (AML), the mucosa-associated-lymphoid-tissue lymphoma-translocation gene 1 (MALT1), A20, NF-κB and MALT1-V1 gene expression levels in CD3⁺ T cells sorted from the peripheral blood of patients with AML were analyzed by real-time PCR. A significantly lower MALT1 and A20 expression level was found in T cells from patients with AML compared with healthy controls (p = 0.045, p < 0.0001); however, the expression level of MALT1-V1 (variant 1) was significantly higher in the AML group than in the healthy control group (p = 0.006), and the expression level of NF-κB was increased in the AML group. In conclusion, the characteristics of the expression pattern of MALT1-A20-NF-κB and the distribution of MALT1 variants in T cells from AML were first characterized. Overall, low TCR-CD3 signaling is related to low MALT1 expression, which may related to T cell immunodeficiency, while the up-regulation of MALT1-V1 may play a role in overcoming the T cell activity by downregulating A20 in patients with AML, which may be related to a specific response to AML-associated antigens.

【 授权许可】

   
2013 Shi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 2011, 4:36. BioMed Central Full Text
• [2]Schläfli AM, Torbett BE, Fey MF, Tschan MP: BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation. Exp Hematol Oncol 2012, 1(1):25. BioMed Central Full Text
• [3]Lin C, Li Y: The role of peptide and DNA vaccines in myeloid leukemia immunotherapy. Cancer Cell Int 2013, 13(1):13. BioMed Central Full Text
• [4]Chen S, Zha X, Yang L, Li B, Liye Z, Li Y: Deficiency of CD3gamma, delta, epsilon, and zeta expression in T cells from AML patient. Hematology 2011, 16(1):31-36.
• [5]Li Y, Geng S, Yin Q, Chen S, Yang L, Wu X, Li B, Du X, Schmidt CA, Przybylski GK: Decreased level of recent thymic emigrants in CD4+ and CD8 + T cells from CML patients. J Transl Med 2010, 8:47. BioMed Central Full Text
• [6]Zha X, Yan X, Shen Q, Zhang Y, Wu X, Chen S, Li B, Yang L, Geng S, Weng J, Du X, Li Y: Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol 2012, 5:74. BioMed Central Full Text
• [7]Li Y: Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology 2008, 13(5):267-275.
• [8]Burmeister T, Molkentin M, Meyer C, Lachmann N, Schwartz S, Friedrichs B, Beyer J, Blau IW, Lohm G, Tietze-bürger C, Marschalek R, Uharek L: Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse. Exp Hematol Oncol 2012, 1(1):6. BioMed Central Full Text
• [9]Li Y, Yin Q, Yang L, Chen S, Geng S, Wu X, Zhong L, Schmidt CA, Przybylski GK: Reduced levels of recent thymic emigrants in acute myeloid leukemia patients. Cancer Immunol Immunother 2009, 58(7):1047-1055.
• [10]Tanchot C, Rocha B: Peripheral selection of T cell repertoires: the role of continuous thymus output. J Exp Med 1997, 186(7):1099-1106.
• [11]Li Y, Chen S, Yang L, Zhou Y, Wu X, Huang M, Geng S: Clonal expanded TCR Vbeta T cells in patients with APL. Hematology 2005, 10(2):135-139.
• [12]Zha X, Chen S, Yang L, Shi L, Li B, Wu X, Lu Y, Li Y: Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol 2012, 31(11):1628-1635.
• [13]Opipari AW, Boguski MS, Dixit VM: The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990, 265(25):14705-14708.
• [14]Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R: Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol 2010, 80(12):2009-2020.
• [15]Zhang F, Yang L, Li Y: The role of A20 in the pathogenesis of lymphocytic malignancy. Cancer Cell Int 2012, 12(1):44. BioMed Central Full Text
• [16]Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M: The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. Nat Immunol 2013, 14(4):337-345.
• [17]Thuille N, Wachowicz K, Hermann-kleiter N, Kaminski S, Fresser F, Lutz-nicoladoni C, Leitges M, Thome M, Massoumi R, Baier G: PKCθ/β and CYLD are antagonistic partners in the NFκB and NFAT transactivation pathways in primary mouse CD3+ T lymphocytes. PLoS One 2013, 8(1):e53709.
• [18]Tewari M, Wolf FW, Seldin MF, O'shea KS, Dixit VM, Turka LA: Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 1995, 154(4):1699-1706.
• [19]Braun FC, Grabarczyk P, Möbs M, Braun FK, Eberle J, Beyer M, Sterry W, Busse F, Schröder J, Delin M, Przybylski GK, Schmidt CA: Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome. Clin Lymphoma Myeloma Leuk 2011, 25(9):1494-1501.
• [20]Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wójtowicz E, Soberon V, Schenten D, Mack B, Reutelshöfer M, Beyaert R, Amann K, van Loo G, Schmidt-supprian M: B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011, 117(7):2227-2236.
• [21]Song XT, Evel-kabler K, Shen L, Rollins L, Huang XF, Chen SY: A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Clin Pract Cardiovasc Med 2008, 14(3):258-265.
• [22]Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J, Sun L, Chen ZJ, Marynen P, Beyaert R: T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008, 9(3):263-271.
• [23]Rebeaud F, Hailfinger S, Posevitz-fejfar A, Tapernoux M, Moser R, Rueda D, Gaide O, Guzzardi M, Iancu EM, Rufer N, Fasel N, Thome M: The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 2008, 9(3):272-281.
• [24]Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok PY, Criswell LA: Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008, 40(9):1062-1064.
• [25]Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M, Geboes L, Louagie E, Mc guire C, Vereecke L, Chu Y, Boon L, Staelens S, Matthys P, Lambrecht BN, Schmidt-supprian M, Pasparakis M, Elewaut D, Beyaert R, van Loo G: A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011, 43(9):908-912.
• [26]Hailfinger S, Rebeaud F, Thome M: Adapter and enzymatic functions of proteases in T-cell activation. Immunol Rev 2009, 232(1):334-347.
• [27]Thome M: Multifunctional roles for MALT1 in T-cell activation. Nat Rev Immunol 2008, 8(7):495-500.
• [28]Hirsch B, Grünbaum M, Wagner F, Bi Y, Lucka L, Du MQ: A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology. Diagn Histopathol (Oxf) 2012, 60(6B):E19-E27.
• [29]Frenzel LP, Claus R, Plume N, Schwamb J, Konermann C, Pallasch CP: Sustained NF-kappaB activity in chronic lymphocytic leukemia is Independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus. Int J Cancer 2011, 128(10):2495-2500.
• [30]Philipp C, Edelmann J, Bühler A, Winkler D, Stilgenbauer S, Küppers R: Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. Int J Cancer 2011, 128(7):1747-1750.